SpringerLink
Log in

Influence of growth hormone therapy on germinoma survivors

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

Due to the effectiveness of growth hormone therapy (GHT), the number of cancer survivors receiving GHT has increased. Previous studies had indicated that GHT was not associated with the increasing risks of tumor recurrence and development with second neoplasm (SN) in cancer survivors. However, to date, research on those risks in germinoma survivors is still limited. The aim of this study is to evaluate the impact of GHT in relation to tumor recurrence and development with SN in pure germinoma survivors.

Methods

This retrospective cohort study was approved by the Ethical Committee for Epidemiology of our institution. Seventy-three consecutive patients who underwent a biopsy of the lesion and were diagnosed with pure germinoma were retrospectively studied. They (median age, 15.0 years) were followed up more than 1 year after biopsy (median follow-up period, 14.3 years). The following data was obtained from the medical records of the patients: age, sex, preoperative magnetic resonance imaging findings, hormonal replacement, and events including tumor recurrence and/or SN.

Results

In our patient series, 16 patients (21.9%) who were more likely to have neurohypophysial lesion and receive multiple hormonal therapies had received GHT. No significant differences in the rates of tumor recurrence and development with SN were observed between the patients who had and had not received GHT. Moreover, the recurrence-free survival and overall survival rates were not different between the patients who had and had not received GHT.

Conclusions

GHT did not increase the risks of tumor recurrence and development with SN in pure germinoma survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR (2019) American association of clinical endocrinologists and American college of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 25(11):1191–1232. https://doi.org/10.4158/GL-2019-0405

    Article  PubMed  Google Scholar 

  2. Brain Tumor Registry of Japan (2017) Report of brain tumor registry of Japan. Neurol Med Chir (Tokyo) 57(Supple1):9–102. https://doi.org/10.2176/nmc.sup.2017-0001

    Article  Google Scholar 

  3. Tamhane S, Sfeir JG, Kittah NEN, Jasim S, Chemaitilly W, Cohen LE, Murad MH (2018) GH therapy in childhood cancer survivors: a systematic review and meta-analysis. J Clin Endocrinol Metab 103(8):2794–2801. https://doi.org/10.1210/jc.2018-01205

    Article  PubMed  Google Scholar 

  4. Alotaibi NM, Noormohamed N, Cote DJ, Alharthi S, Doucette J, Zaidi HA, Mekary RA, Smith TR (2018) Physiologic growth hormone-replacement therapy and craniopharyngioma recurrence in pediatric patients: a meta-analysis. World Neurosurg 109:487–496. https://doi.org/10.1016/j.wneu.2017.09.164

    Article  PubMed  Google Scholar 

  5. Jasim S, Alahdab F, Ahmed AT, Tamhane SU, Sharma A, Donegan D, Nippoldt TB, Murad MH (2017) The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer, and stroke. Endocrine 56(2):267–278. https://doi.org/10.1007/s12020-016-1156-6

    Article  PubMed  CAS  Google Scholar 

  6. Shen L, Sun CM, Li XT, Liu CJ, Zhou YX (2015) Growth hormone therapy and risk of recurrence/progression in intracranial tumors: a meta-analysis. Neurol Sci 36(10):1859–1867. https://doi.org/10.1007/s10072-015-2269-z

    Article  PubMed  Google Scholar 

  7. Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, Ohara A, Mizutani S (2013) Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 98(1):74–88. https://doi.org/10.1007/s12185-013-1364-2

    Article  PubMed  Google Scholar 

  8. Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T (1997) Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg 86(3):446–455. https://doi.org/10.3171/jns.1997.86.3.0446

    Article  PubMed  CAS  Google Scholar 

  9. Higham CE, Johannsson G, Shalet SM (2016) Hypopituitarism. Lancet 388(12):2403–2415. https://doi.org/10.1016/S0140-6736(16)30053-8

    Article  PubMed  CAS  Google Scholar 

  10. Losa M, Castellino L, Pagnano A, Rossini A, Mortini P, Lanzi R (2020) Growth hormone therapy does not increase the risk of craniopharyngioma and nonfunctioning pituitary adenoma recurrence. J Clin Endocrinol Metab 105(5):1573–1580. https://doi.org/10.1210/clinem/dgaa089

    Article  Google Scholar 

  11. Smith TR, Cote DJ, Jane JA, Laws ER (2016) Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study. J Neurosurg Pediatr 18(4):408–412. https://doi.org/10.3171/2016.4.PEDS16112

    Article  PubMed  Google Scholar 

  12. Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson B, Jakobsson KE, Jarfelt M, Johannsson G, Nilsson AG (2012) Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol 166(6):1061–1068. https://doi.org/10.1530/EJE-12-0077

    Article  PubMed  CAS  Google Scholar 

  13. Leung W, Rose SR, Zhou Y, Hancock ML, Burstein S, Schriock EA, Lustig R, Danish RK, Evans WE, Hudson MM, Pui CH (2002) Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 20(13):2959–2964. https://doi.org/10.1200/JCO.2002.09.142

    Article  PubMed  CAS  Google Scholar 

  14. Packer RJ, Boyett JM, Janss AJ, Stavrou T, Kun L, Wisoff J, Russo C, Geyer R, Phillips P, Kieran M, Greenberg M, Goldman S, Hyder D, Heideman R, Jones-Wallace D, August GP, Smith SH, Moshang T (2001) Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19(2):480–487. https://doi.org/10.1200/JCO.2001.19.2.480

    Article  PubMed  CAS  Google Scholar 

  15. Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, Rossi WC, Feudtner C, Murad MH, Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (2016) Guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-i deficiency. Horm Res Paediatr 86(6):361–397. https://doi.org/10.1159/000452150

    Article  PubMed  CAS  Google Scholar 

  16. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, Armstrong GT, Meadows A, Stovall M, Robison LL, Meacham LR (2014) Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 99(6):2030–2037. https://doi.org/10.1210/jc.2013-4159

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Hartman ML, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB, Chipman JJ, Melmed S, International HypoCCS Advisory Board (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab 98(3):980–988. https://doi.org/10.1210/jc.2012-2684

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Krzyzanowska-Mittermayer K, Mattsson AF, Maiter D, Feldt-Rasmussen U, Camacho-Hübner C, Luger A, Abs R (2018) New neoplasm during GH replacement in adults with pituitary deficiency following malignancy: a KIMS analysis. J Clin Endocrinol Metab 103(2):523–531. https://doi.org/10.1210/jc.2017-01899

    Article  PubMed  Google Scholar 

  19. Swerdlow AJ, Cooke R, Beckers D, Borgström B, Butler G, Carel JC, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Gausche R, Giacomozzi C, Hokken-Koelega ACS, Khan AJ, Kiess W, Kuehni CE, Mullis PE, Pfaffle R, Sävendahl L, Sommer G, Thomas M, Tidblad A, Tollerfield S, Van Eycken L, Zandwijken GRJ (2017) Cancer risks in patients treated with growth hormone in childhood: the SAGhE European Cohort Study. J Clin Endocrinol Metab 102(5):1661–1672. https://doi.org/10.1210/jc.2016-2046

    Article  PubMed  Google Scholar 

  20. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA (2006) Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91(9):3494–3498. https://doi.org/10.1210/jc.2006-0656

    Article  PubMed  CAS  Google Scholar 

  21. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87(7):3136–3141. https://doi.org/10.1210/jcem.87.7.8606

    Article  PubMed  CAS  Google Scholar 

  22. Inskip PD, Sigurdson AJ, Veiga L, Bhatti P, Ronckers C, Rajaraman P, Boukheris H, Stovall M, Smith S, Hammond S, Henderson TO, Watt TC, Mertens AC, Leisenring W, Stratton K, Whitton J, Donaldson SS, Armstrong GT, Robison LL, Neglia JP (2016) Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects. Int J Radiat Oncol Biol Phys 94(4):800–807. https://doi.org/10.1016/j.ijrobp.2015.11.046

    Article  PubMed  Google Scholar 

  23. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM (2010) Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 28(36):5287–5293. https://doi.org/10.1200/JCO.2009.27.0090

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Enago for the English language review.

Funding

This study was partially supported by JSPS KAKENHI (Grant Number: JP19K17987).

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 7348551, Japan

    Yasuyuki Kinoshita, Fumiyuki Yamasaki, Akira Taguchi, Takeshi Takayasu, Ushio Yonezawa & Nobutaka Horie

  2. Department of Neurosurgery and Neuro-Endovascular Therapy, Hiroshima Prefectural Hospital, Hiroshima, Japan

    Atsushi Tominaga

  3. Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

    Kazunori Arita

  4. Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

    Satoshi Okada

  5. Department of Clinical Oncology and Neuro-Oncology Program, Hiroshima University Hospital, Hiroshima, Japan

    Kazuhiko Sugiyama

Authors
  1. Yasuyuki Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fumiyuki Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akira Taguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeshi Takayasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ushio Yonezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazunori Arita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nobutaka Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuhiko Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YK: Conception and design. YK, FY, ATa, TT, UY, ATo, KA, SO, and KS: Acquisition of data. YK: Analysis and interpretation. YK: Drafting the article. FY, ATo, NH, and KS: Critically revising the article. KS: Study supervision. All authors reviewed the manuscript.

Corresponding author

Correspondence to Yasuyuki Kinoshita.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest in association with the present study.

Ethical approval

This study was approved by the Ethical Committee for Epidemiology of Hiroshima University (E-2385–1).

Informed consent

The contents of this manuscript have not been published in full elsewhere in any form.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kinoshita, Y., Yamasaki, F., Taguchi, A. et al. Influence of growth hormone therapy on germinoma survivors. Pituitary 25, 854–860 (2022). https://doi.org/10.1007/s11102-022-01273-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-022-01273-5

Keywords

Search

Navigation